Glofit-GemOX

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Dr. Haifaa Abdulhaq presents results from the global Phase III STARGLO trial, demonstrating the superior overall survival, progression-free survival, and complete response rates of glofitamab combined with gemcitabine and oxaliplatin (Glofit-GemOx) versus rituximab-based therapy (R-GemOx) in relapsed/refractory diffuse large B-cell lymphoma, with a tolerable safety profile.

Glofitamab plus Gemcitabine and Oxaliplatin (Glofit-GemOx) for Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL): Results of a Global Randomized Phase III Trial (STARGLO)